Premium
Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab
Author(s) -
Unal Sule,
Sag Erdal,
Kuskonmaz Baris,
Kesici Selman,
Bayrakci Benan,
Ayvaz Deniz C.,
Tezcan Ilhan,
Yalnızoglu Dilek,
Uckan Duygu
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24799
Subject(s) - medicine , myasthenia gravis , rituximab , asymptomatic , hematopoietic stem cell transplantation , methylprednisolone , mycophenolate , transplantation , surgery , gastroenterology , lymphoma
Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2‐year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post‐transplant +22nd month and required respiratory support with mechanical ventilation. She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance. She is currently asymptomatic on the 6th month of follow‐up. Pediatr Blood Cancer 2014;61:928–930. © 2013 Wiley Periodicals, Inc.